Strikingly, AML patients with a high level of PD-1+Foxp3+ γδ T cells were found to have poor OS (PD-1+Foxp3+high vs. PD-1+Foxp3+low, 24-month OS 20% vs. 64%, P = 0.034), suggesting that the high proportion of the PD-1+Foxp3+ γδ T subset was associated with poor clinical outcome (Figure 4F). This evidence concerns the gene FOXP3 and acute myeloid leukemia.